In 2016, I was the first author on a paper published in Blood: Targeting of the bone marrow microenvironment improves outcome in a murine model of myeodysplastic syndrome. (Feb4; 127(5): 616-25. I have an ongoing laboratory project in which I am testing the theory that improvement of residual normal hematopoiesis in myelodysplastic syndromes may be able to delay or stop clonal, dysfunctional hematopoiesis that is the hallmark of this group of diseases.
I am the site PI for a drug-company sponsored clinical trial to test an agent for treatment of acute gastrointestinal graft versus host disease. This trial will likely open at Roswell Park in the next several months. Additionally, I have written a protocol that is in the process of going through regulatory committees at Roswell Park. If approved, I will be the PI of this investigator initiated study in which haploidentical allogenic bone marrow transplants use peripheral blood as the source of hematopoietic stem cells rather than whole bone marrow.